ROCKET STOCK…. SURYA PHARMA Ltd. At 90/-; EPS 40/- TARGET 135/- & 185/-
Published on Thursday, June 18th, 2009 at 7:58 PMAuthor: india_bulls (144 Articles)
ROCKET STOCK…. SURYA PHARMA Ltd. At 90/-; EPS 40/- TARGET 135/- & 185/-
BUY SURYA PHARMA Ltd at 90/- Target 135/- and 185/-
BUY SURYA PHARMA Ltd 10/- face Value Trading in BSE & NSE at 90/- . Immediate Target 135/- ; Short term Target 185/- . And 255/- for Medium Term.
Good Buy Surya Pharma Lts 10/- face Value Trading at 90/- Risk is very very less because company stock was very Valuable because Book value at 165/ and EPS 40/- for 2008-2009 PE 2.5. Pharma Industry Average PE was 15. If you take 5 PE it will go 200/- minimum. As per PE 10 It will go 400/- any time. Just Buy and hold 1 month with good appreciation at 100% Profit.
Lot of Accumulation is going on in NSE an BSE by Company circle people and opearators Because Company stock has good valuable at 95/-.
Surya Pharma recorded total Revenues of 730 Crores and Net Profit 56 Cr for the year ended March 2009. Equity 14.4 Crores EPS 39.95 and PE 2.5; Book Value 165/- . In this 2009 -2010 year Expansion Income will adding; So For 2009- 2010 projection Revenue 958 Cr and Net Profit 75 Cr. EPS 50/- and PE 2. Company having lot of Expansion Plans in future; Surya pharma is targeting 2000+ cr revenues by 2012. Lot of Future for Surya Pahram; Its Multi bagger stock in Future.
I believe it may capitalize its general reserves and reward with BONUS shares to the share holders in the coming years.
Share Holding:-
The Promoters holding 35%, Corporate bodies hold 37%, and Public only 25% Others 3%.
Book value 165/- for 2008-2009.
Surya pharma an ISO 9001:2000 company engaged in manufacturing, developing, and marketing of various Bulk drugs / Active Pharma Ingredients (API) from past Sixteen years. More than 60% of the production is exported to Bulk drug buyers in the international market. It is also focused on contract research manufacturing services. It has comprehensive research & development facilities, skillful application of the latest processes and innovative production techniques. Surya pharma operates presently on five facilities to their full capacity at Baddi (2), Punjab (1) Panchakula (1) and Sambha in Jammu & Kashmir (1). Surya Pharma record a spectacular fifty fold growth rate as a multi-product and multi unit pharmaceutical company with the turnover over. Rs. 7 Billion and a reputation built on the cornerstones of continuous process up gradation. Commercial production is carried out in plants operating as per GMP standards and equipped with quality equipment, with a total capacity exceeding 5, 40,000 liters.
Surya Pharma has a well established marketing network in India and across the globe. More than 60% of the total production is exported to Europe, SE Asia, the Far East, Middle East, Latin America and Africa. Achieving high quality cost effective manufacturing solutions for customers needs is the basis of its business and essential to the success. At Surya Pharmaceuticals, research and development is the backbone of its business model, which maximizes process technology, minimizes process loss, enhances yield and helps develop new products. Since inception, the company has a dedicated R&D centre with state-of-art facilities. The R & D team is consistently working on introduction of advanced version of existing products , reduced the number of steps involved and increasing cost-competitiveness. The focus of the Research & Development activities is the same namely development of new products , new processes , techniques, increased efficiencies, cost reduction ,reduction of fuel consumption, better economies with the best quality etc. Company has a dedicated and fully equipped research centre at Panchkula approved by DSIR (Directorate of Scientific and Industrial Research). The centre has a library, training centre, instrument labs and synthetics labs, all well equipped with the latest high-tech state-of-the-art instruments. All the units have independent process development labs to improve the existing processes. R&D centre has 60 dedicated scientific brains including Doctorates, who are working day & night for introduction of newmolecules.
Surya made a foray into the contract manufacturing space; Surya is now increasing its focus on the contract research area. The company is in advanced stage of negotiation with a British company for the development of a cost-effective process for a new molecule. Surya expects that partnering with the British company at this early stage of development will open up huge contract manufacturing orders for it, once the molecule gets commercialized. However, as the deal has not yet been finalized
Surya has also initiated construction of a new plant in the tax-haven state of Jammu. The Jammu plant will be constructed in line with the US Food and Drug Administration (US FDA) standards primarily to manufacture new APIs and sterile cephalosporins. With the commissioning of this facility, Surya will enter the high margin injectable business. Expecting the Jammu facility to contribute an incremental Rs150 crore to Surya`s revenues in FY2010. Also, with expansion of its API capacity, Surya is also entering the high-end therapeutic segments like anticancer. It also diversifying into healthcare business.
Regulatory Affairs Dept. has an excellent team of professionals having good understanding of concepts of quality systems and cGMP. Drug master files and dossiers are drafted for submission to EDQM, FDA and other regulatory authorities. Internal audits are performed to check the compliance as per cGMP norms. Banur facility has been approved by Ranbaxy & Glaxo. The Panchkula facility is approved by DAI and the Baddi formulation facility is approved by Cipla, Wockhardt, Helm AG, German Remedies and Elder. The API unit at Baddi has been approved by Ranbaxy. All the facilities are under up gradation for US FDA / European regulatory compliance. The company and its manufacturing units are ISO 9001-2000 certified by international accreditation agency. The company is a certified Three Star Export House.
Menthol & Mint is now a major activity at Surya. Mint manufactured by it is great demand around the world for flavoring confectionery, Chewing gum, Cigarettes and Toothpastes. It`s also used in Shaving gels, Shampoos and a wide range of cosmetics. Also in India, Mint has a wide application in pan masala, gutka, zarda (chewing tobacco) & scented betel nut.
In addition to its much loved cooling effect Mint from Surya is also used for its therapeutic qualities in pharmaceutical products like medicated strips, pain balms and cough syrups. Catering to a wide range of Menthol and Mint oil requirements, it assures the customers a regular supply and consistent quality. At Surya, customer satisfaction forms the key note of all operations. As it will continue to do so in the next millennium. Surya has recently entered the business of manufacturing menthol and its derivatives. The company primarily intends to sell these products to its overseas clients, and the company has started exporting these products in August 2007. Expecting the menthol business to add Rs 150 crore to Surya`s turnover in FY2010. Surya pharma is targeting 2000+ cr revenues by 2012.
Positive Points for this stock for Up moving:
1) Company Circle people and Operators are accumulating at current price. Because Company Stock Good Value at 05/- EPS 40/- PE 2.5 and Book Value at 165/- Equity is very small at 14.4 Cr promoters Holding 35%
2) 10% Dividend Paying Company
3) Coming Years Bonus Expecting Good reserves and Good Book Value.
4) Company having lot of Expansion Plans.
5) For this year Expected Revenue 958 Cr and NetProfti 75 Crores EPS 50/- PE 2. In Pharma Companies Avarage PE was 15. If we take at least 5, It will go minimum 200/-.
BIG BULLS
Mumbai
Subscribe to my newsletter filling the form below. I'll try to make you happy.
Related Posts :
|
|
|
Market Live |
|
|
Loading ...